株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

プラスミノゲン活性化因子阻害剤1:パイプライン製品の分析

Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 374384
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.10円で換算しております。
プラスミノゲン活性化因子阻害剤1:パイプライン製品の分析 Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2019
出版日: 2019年12月27日 ページ情報: 英文 70 Pages
概要

当レポートでは、プラスミノゲン活性化因子阻害剤1 を標的とした治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

プラスミノゲン活性化因子阻害剤1 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別

パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で開発中の製品

治療薬の評価

  • 単剤/併用治療薬の場合
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • D-Pharm Ltd.
  • Jazz Pharmaceuticals Plc

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

主なニュースおよびプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Accendatech Au Pty Ltd, H2 2019
  • Pipeline by Beam Therapeutics Inc, H2 2019
  • Pipeline by Jazz Pharmaceuticals Plc, H2 2019
  • Pipeline by MDI Therapeutics Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC2013TDB

Summary

According to the recently published report 'Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2019'; Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 12 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis. PAI-1 is mainly produced by the endothelium and also by other tissue types, such as adipose tissue. PAI-1 inhibits the serine proteases tPA and urokinase and hence inhibit the physiological process that degrades blood clots. PAI-1 inhibits the activity of matrix metalloproteinases (important role in invasion of malignant cells across the basal lamina).

The report 'Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2019' outlays comprehensive information on the Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 7 molecules, respectively. Report covers products from therapy areas Cardiovascular, Oncology, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Respiratory, Immunology, Genetic Disorders, Metabolic Disorders and Undisclosed which include indications Arterial Thrombosis, Idiopathic Pulmonary Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Renal Failure, Alpha-1 Antitrypsin Deficiency (A1AD), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Emphysema, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hepatic Veno-Occlusive Disease, Inflammatory Bowel Disease, Interstitial Lung Fibrosis, Metastatic Lung Cancer, Multiple Sclerosis, Neuromyelitis Optica (Devic's Syndrome), Neurotoxicity Syndromes, Obesity, Pediatric Diffuse Intrinsic Pontine Glioma, Solid Tumor, Stroke, Systemic Sclerosis (Scleroderma), Thromboembolism, Thrombosis, Thrombotic Microangiopathy, Unspecified and Venous (Vein) Thrombosis.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)
  • The report reviews Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Overview
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Companies Involved in Therapeutics Development
  • Accendatech Au Pty Ltd
  • Beam Therapeutics Inc
  • Jazz Pharmaceuticals Plc
  • MDI Therapeutics Inc
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Drug Profiles
  • ACT-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bispecific Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • defibrotide sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate SERPINA1 for Alpha-1 Antitrypsin Deficiency - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MDI-2268 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MDI-2517 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SK-216 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TM-5275 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TM-5441 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TM-5484 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TM-5614 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Dormant Products
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Discontinued Products
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 07, 2019: Jazz Pharmaceuticals to present abstracts on Defitelio (defibrotide sodium) at ASH 2019 Annual Meeting
  • Oct 10, 2019: Jazz Pharmaceuticals announces first patient enrolled in phase 2 clinical trial evaluating defibrotide for the prevention of CAR-T Associated Neurotoxicity
  • May 16, 2019: Jazz Pharmaceuticals to present new data on defitelio at upcoming EHA Congress
  • Mar 25, 2019: Experimental drug reverses high cholesterol, obesity-related nonalcoholic fatty liver disease in animals
  • Nov 28, 2018: Jazz Pharmaceuticals to present data on Defitelio at ASH 2018 Annual Meeting
  • Oct 17, 2018: New Drug Application Filed for defibrotide sodium
  • Feb 23, 2018: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease
  • Nov 01, 2017: Jazz Pharmaceuticals to Present Abstracts on Defitelio at ASH 2017 Annual Meeting
  • Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients
  • Nov 07, 2016: Jazz Pharmaceuticals to Present New Data on Defitelio at the Annual ASH Meeting
  • Aug 02, 2016: CMS Grants New Technology Add-On Payment to Defitelio for the Treatment of Hepatic Veno-Occlusive Disease with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation
  • Mar 30, 2016: FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow
  • Mar 30, 2016: Jazz Pharmaceuticals Announces Webcast for Defitelio (defibrotide sodium) Investor Update
  • Feb 18, 2016: Jazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting
  • Feb 01, 2016: Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer